Elisabetta Morini

Dr. Elisabetta Morini

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZMZachariah L. McLean
Zachariah L. McLean
DGDadi Gao
Dadi Gao
KCKevin Correia
Kevin Correia
JRJennie C. L. Roy
Jennie C. L. Roy
SSShota Shibata
Shota Shibata
JGJames F. Gusella
James F. Gusella
Huntington’s disease (HD) is a dominant neurological disorder caused by an expanded HTT exon 1 CAG repeat that lengthens huntingtin’s polyglutamine tract. Lowering mutant huntingtin has been proposed for treating HD, but genetic modifiers implicate somatic CAG repeat expansion as the driver of onset. We find that branaplam and risdiplam, small molecule splice modulators that lower huntingtin by promoting HTT pseudoexon inclusion, also decrease expansion of an unstable HTT exon 1 CAG repeat in an engineered cell model. Targeted CRISPR-Cas9 editing shows this effect is not due to huntingtin lowering, pointing instead to pseudoexon inclusion in PMS1. Homozygous but not heterozygous inactivation of PMS1 also reduces CAG repeat expansion, supporting PMS1 as a genetic modifier of HD and a potential target for therapeutic intervention. Although splice modulation provides one strategy, genome-wide transcriptomics also emphasize consideration of cell-type specific effects and polymorphic variation at both target and off-target sites.

7 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
DGDadi Gao
Dadi Gao
EMElisabetta Morini
Elisabetta Morini
MSMonica Salani
Monica Salani
AKAram J. Krauson
Aram J. Krauson
ACAnil Chekuri
Anil Chekuri
SSSusan A. Slaugenhaupt
Susan A. Slaugenhaupt
Pre-mRNA splicing is a key controller of human gene expression. Disturbances in splicing due to mutation lead to dysregulated protein expression and contribute to a substantial fraction of human disease. Several classes of splicing modulator compounds (SMCs) have been recently identified and establish that pre-mRNA splicing represents a target for therapy. We describe herein the identification of BPN-15477, a SMC that restores correct splicing of ELP1 exon 20. Using transcriptome sequencing from treated fibroblast cells and a machine learning approach, we identify BPN-15477 responsive sequence signatures. We then leverage this model to discover 155 human disease genes harboring ClinVar mutations predicted to alter pre-mRNA splicing as targets for BPN-15477. Splicing assays confirm successful correction of splicing defects caused by mutations in CFTR, LIPA, MLH1 and MAPT. Subsequent validations in two disease-relevant cellular models demonstrate that BPN-15477 increases functional protein, confirming the clinical potential of our predictions.

20 February 2023 in The American Journal of Human Genetics
Verified
Journal Article
Open access
EMElisabetta Morini
Elisabetta Morini
ACAnil Chekuri
Anil Chekuri
ELEmily M. Logan
Emily M. Logan
JBJessica M. Bolduc
Jessica M. Bolduc
EKEmily G. Kirchner
Emily G. Kirchner
SSSusan A. Slaugenhaupt
Susan A. Slaugenhaupt
Familial dysautonomia (FD) is a rare neurodegenerative disease caused by a splicing mutation in elongator acetyltransferase complex subunit 1 (ELP1). This mutation leads to the skipping of exon 20 and a tissue-specific reduction of ELP1, mainly in the central and peripheral nervous systems. FD is a complex neurological disorder accompanied by severe gait ataxia and retinal degeneration. There is currently no effective treatment to restore ELP1 production in individuals with FD, and the disease is ultimately fatal. After identifying kinetin as a small molecule able to correct the ELP1 splicing defect, we worked on its optimization to generate novel splicing modulator compounds (SMCs) that can be used in individuals with FD. Here, we optimize the potency, efficacy, and bio-distribution of second-generation kinetin derivatives to develop an oral treatment for FD that can efficiently pass the blood-brain barrier and correct the ELP1 splicing defect in the nervous system. We demonstrate that the novel compound PTC258 efficiently restores correct ELP1 splicing in mouse tissues, including brain, and most importantly, prevents the progressive neuronal degeneration that is characteristic of FD. Postnatal oral administration of PTC258 to the phenotypic mouse model TgFD9;Elp1Δ20/flox increases full-length ELP1 transcript in a dose-dependent manner and leads to a 2-fold increase in functional ELP1 in the brain. Remarkably, PTC258 treatment improves survival, gait ataxia, and retinal degeneration in the phenotypic FD mice. Our findings highlight the great therapeutic potential of this novel class of small molecules as an oral treatment for FD.

15 December 2021 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
ACAnil Chekuri
Anil Chekuri
ELEmily M Logan
Emily M Logan
AKAram J Krauson
Aram J Krauson
MSMonica Salani
Monica Salani
SASophie Ackerman
Sophie Ackerman
EMElisabetta Morini
Elisabetta Morini
Familial dysautonomia (FD) is an autosomal recessive neurodegenerative disease caused by a splicing mutation in the gene encoding Elongator complex protein 1 (ELP1, also known as IKBKAP). This mutation results in tissue-specific skipping of exon 20 with a corresponding reduction of ELP1 protein, predominantly in the central and peripheral nervous system. Although FD patients have a complex neurological phenotype caused by continuous depletion of sensory and autonomic neurons, progressive visual decline leading to blindness is one of the most problematic aspects of the disease, as it severely affects their quality of life. To better understand the disease mechanism as well as to test the in vivo efficacy of targeted therapies for FD, we have recently generated a novel phenotypic mouse model, TgFD9; IkbkapΔ20/flox. This mouse exhibits most of the clinical features of the disease and accurately recapitulates the tissue-specific splicing defect observed in FD patients. Driven by the dire need to develop therapies targeting retinal degeneration in FD, herein, we comprehensively characterized the progression of the retinal phenotype in this mouse, and we demonstrated that it is possible to correct ELP1 splicing defect in the retina using the splicing modulator compound (SMC) BPN-15477.

4 February 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
DGDadi Gao
Dadi Gao
EMElisabetta Morini
Elisabetta Morini
MSMonica Salani
Monica Salani
AKAram J. Krauson
Aram J. Krauson
ARAshok Ragavendran
Ashok Ragavendran
SSSusan A. Slaugenhaupt
Susan A. Slaugenhaupt
Pre-mRNA splicing is a key control point in human gene expression. Disturbances in splicing due to mutation or aberrant splicing regulatory networks lead to dysregulated protein expression and contribute to a substantial fraction of human disease. Several classes of active and selective splicing modulator compounds have been recently identified, thus proving that pre-mRNA splicing is a viable target for therapy. We describe herein the identification of BPN-15477, a novel splicing modulator compound, that restores correct splicing of exon 20 in the Elongator complex protein 1 (ELP1) gene carrying the major IVS20+6T>C mutation responsible for familial dysautonomia. We then developed a machine learning approach to evaluate the therapeutic potential of BPN-15477 to correct splicing in other human genetic diseases. Using transcriptome sequencing from compound-treated fibroblast cells, we identified treatment responsive sequence signatures, the majority of which center at the 5’ splice site of exons whose inclusion or exclusion is modulated by SMC treatment. We then leveraged this model to identify 155 human disease genes that harbor ClinVar mutations predicted to alter pre-mRNA splicing as potential targets for BPN-15477 treatment. Using in vitro splicing assays, we validated representative predictions by demonstrating successful correction of splicing defects caused by mutations in genes responsible for cystic fibrosis ( CFTR ), cholesterol ester storage disease ( LIPA ), Lynch syndrome ( MLH1 ) and familial frontotemporal dementia ( MAPT ). Our study shows that deep learning techniques can identify a complex set of sequence signatures and predict response to pharmacological modulation, strongly supporting the use of in silico approaches to expand the therapeutic potential of drugs that modulate splicing.

27 November 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SYShuqi Yun
Shuqi Yun
ACAnil Chekuri
Anil Chekuri
JAJennifer Art
Jennifer Art
KKKrishnakanth Kondabolu
Krishnakanth Kondabolu
SSSusan A. Slaugenhaupt
Susan A. Slaugenhaupt
CAChristiano R. R. Alves
Christiano R. R. Alves
Familial dysautonomia (FD) is a fatal inherited congenital neuropathy characterized by both progressive neurological symptoms and systemic abnormalities, and patients have a reduced life expectancy. FD is caused by a T-to-C mutation in intron 20 of the Elongator acetyltransferase complex subunit 1 (ELP1) gene, which affects the ELP1 splicing process by causing tissue-specific skipping of exon 20. Here, we developed a CRISPR base editor (BE) approach capable of precisely correct this mutation. Using Cas9 variants and screening multiple gRNAs, we selected an optimized BE combination that was able to promote up to 70% on-target editing in HEK293T cells harboring the ELP1 T-to-C mutation. These editing levels were sufficient to rescue more than 50% of ELP1 transcripts with precise exon 20 inclusion. Moreover, an engineered dual intein-split system was optimized to deliver these constructs in vivo. We packaged these novel constructs in adeno-associated virus (AAV) vectors for further testing in iPSC-derived sympathetic neurons and a mouse model harboring the human ELP1 T6C gene. Our strategy could effectively correct the ELP1 splicing defects in vivo and culminated in phenotypic recovery in human neurons. Minimal off-target editing was observed demonstrating high levels of specificity with these optimized base editors. Therefore, we engineered and validated novel base editor approaches to correct the ELP1 TC6 mutation and ELP1 splicing defect and provided essential proof of concept data towards a permanent treatment for FD.